| Literature DB >> 26538828 |
Pinja Ilmarinen1, Leena E Tuomisto1, Hannu Kankaanranta2.
Abstract
Asthma is a heterogeneous disease with many phenotypes, and age at disease onset is an important factor in separating the phenotypes. Genetic factors, atopy, and early respiratory tract infections are well-recognized factors predisposing to childhood-onset asthma. Adult-onset asthma is more often associated with obesity, smoking, depression, or other life-style or environmental factors, even though genetic factors and respiratory tract infections may also play a role in adult-onset disease. Adult-onset asthma is characterized by absence of atopy and is often severe requiring treatment with high dose of inhaled and/or oral steroids. Variety of risk factors and nonatopic nature of adult-onset disease suggest that variety of mechanisms is involved in the disease pathogenesis and that these mechanisms differ from the pathobiology of childhood-onset asthma with prevailing Th2 airway inflammation. Recognition of the mechanisms and mediators that drive the adult-onset disease helps to develop novel strategies for the treatment. The aim of this review was to summarize the current knowledge on the pathogenesis of adult-onset asthma and to concentrate on the mechanisms and mediators involved in establishing adult-onset asthma in response to specific risk factors. We also discuss the involvement of these mechanisms in the currently recognized phenotypes of adult-onset asthma.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26538828 PMCID: PMC4619972 DOI: 10.1155/2015/514868
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Currently identified phenotypes of adult/late-onset asthma based on published cluster analysis studies. ICS = inhaled corticosteroid, NSAID = nonsteroidal anti-inflammatory drug, OCS = oral corticosteroid, and FEV1 = forced expiratory volume in 1 second.
Background information of cluster analyses including characterization of phenotypes of adult-onset asthma.
| Study | Patient | Duration of asthma (mean/median years) | Patients with early-onset asthma included | Severity levels included | Major comorbidities (other than rhinitis/atopy) included as input or outcome variables | Smokers included | Other exclusion criteria | Study setting | Variables related to biomarkers included in cluster analysis |
|---|---|---|---|---|---|---|---|---|---|
| Haldar et al. 2008 [ | (a) 184 | NR | Yes | (a) Mild-to-moderate, (b-c) refractory | (b) Scores for anxiety (input), depression and hyperventilation syndrome | Ex-smokers with <10 pack-years | (c) Therapy nonadherence | (a-b) CS | Sputum eosinophil count |
|
| |||||||||
| Moore et al. 2010 [ | (d) 726 | 22 | Yes | All | Aspirin sensitivity/polyps, pneumonia/bronchitis, sinus disease, GERD, and hypertension (all input, included in composite variables) | Ex-smokers with <5 pack-years | Age below 12 years | CS | None |
|
| |||||||||
| Siroux et al. 2011 [ | (e) 1895 | NR | Yes | All | Eczema (input) | Yes | (e) Age below 20 years | CS (population-based) | Total IgE |
|
| |||||||||
| Amelink et al. 2013 [ | (g) 200 | 10 | No | All | NSAID sensitivity (input), history of nasal polyposis, and reflux symptoms/medication | Yes if ≥12% FEV1 reversibility after salbutamol inhalation and normal diffusion capacity. | Respiratory symptoms or chronic lung diseases during childhood, other pulmonary diseases, or nonrelated major comorbidities, pregnancy. | CS | Sputum eosinophils, total IgE |
|
| |||||||||
| Kim et al. 2013 [ | (h) 724 | NR | Yes | All | None | Yes | (h) Subjects with destroyed lungs, bronchiectasis or lung resection, age below 18 years | (h) L (1 year) | None |
|
| |||||||||
| Newby et al. 2014 [ | (j) 349 | NR | Yes | Severe refractory | Scores for anxiety and depression, reflux history, nasal polyps, and eczema | Yes | NR | L (median 3 years) | Blood eosinophil count, total IgE |
|
| |||||||||
| Schatz et al. 2014 [ | (k) 3612 | NR | Yes | Difficult-to-treat asthma (all) | Aspirin sensitivity, atopic dermatitis (input) | Yes, smoking history ≤30 pack-years | (k) Age below 12 years | L (1 year) | Total IgE |
|
| |||||||||
| Kaneko et al. 2013 [ | (l) 880 | NR | Yes | All | None | Yes | NR | CS | Total IgE |
NR = not reported, GERD = gastroesophageal reflux disease, NSAID = nonsteroidal anti-inflammatory drug, and FEV1 = forced expiratory volume in 1 second. (a), (b), and (c) Patients recruited from several different studies and sources (a = primary care, b = secondary care, c = data from a prospective clinical study), (d) SARP = the Severe Asthma Research Network, (e) ECRHSII = European Community Respiratory Health Survey, (f) EGEA2 = Epidemiological Study on the Genetics and Environment of Asthma, (g) patients recruited from hospitals in Amsterdam, (h) COREA = Cohort for Reality and Evolution of Adult Asthma in Korea, (i) SCH = Korean asthma cohort of Soonchunhyang University Asthma Genome Research Centre, (j) patients from British Thoracic Society Severe Refractory Asthma Registry, (k) TENOR = The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens, and (l) patients recruited from University of Tsukuba Hospital, Hokkaido University Hospital, or their affiliated hospitals, Japan. Defined as age at onset <18 years.
Biological mediators and biomarkers suggested to be involved in adult/late-onset asthma.
| Mediator | Level of asthma severity included | Inclusion of patients with adult/late-onset asthma | Main finding concerning the role of mediators in adult/late-onset asthma. | References | Adult/late-onset phenotype with possible significance |
|---|---|---|---|---|---|
| Periostin | Severe | 80% with late-onset asthma | Higher levels in patients with fixed airflow limitation and eosinophilic inflammation. | Bobolea et al. 2015 [ | Eosinophilic inflammation-predominant |
|
| |||||
| Eotaxin-2 | All | Groups of early- and late-onset asthma compared | Patients with severe asthma showed higher epithelial expression of eotaxin-2. Levels of eotaxin-2 positively correlated with age of asthma onset, sputum eosinophils, and number of exacerbations and negatively correlated with FEV1 % predicted. Among patients with late-onset (but not early-onset) asthma, eotaxin-levels were higher in those with severe asthma. Sputum eosinophilia was more common among patients with late-onset asthma. | Coleman et al. 2012 [ | Eosinophilic inflammation-predominant |
|
| |||||
| L-arginine/ADMA | Severe | Groups of early- and late-onset asthma compared | Lower L-arginine/ADMA ratio and negative correlation to BMI in late- versus early-onset asthma; may partly explain the inverse relationship between FeNO and BMI. Reduced L-arginine/ADMA ratio associated with reduced IgE and lung volumes, increased respiratory symptoms, and worse quality of life in late- but not early-onset asthma. | Holguin et al. 2013 [ | Obesity-related asthma |
|
| |||||
| Leptin | All | Obese women with adult-onset asthma | Leptin in visceral fat associated with AHR but not airway inflammation. Adipokine receptor was expressed in airway epithelium suggesting direct effects of adipokines on the airways. | Sideleva et al. 2012 [ | Obesity-related asthma |
| All | Nonobese women with newly-onset adult asthma | Leptin correlated positively with asthma symptom score and negatively with lung function even though no difference was found on adipokine levels between patients with asthma and healthy subjects. High baseline resistin predicted steeper decrease in serum ECP, EPX, and MPO during glucocorticoid treatment. | |||
|
| |||||
| YKL-40 | All | Late- and early-onset groups compared | Levels of YKL-40 were higher in asthma with poor control and exacerbations and atopy. When phenotypes were compared, highest levels of YKL-40 in obesity-related asthma and early-onset atopic asthma. Lower levels in nonatopic late-onset asthma. | Specjalski et al. 2015 [ | Obesity-related (and early-onset atopic) |
|
| |||||
| IFN- | All | Patients with moderate and severe asthma compared, approx. 85% with asthma onset ≥12 years in both groups | Levels of IFN- | Shannon et al. 2008 [ | Severe and obstructive asthma? |
|
| |||||
|
| All | Groups of child- and adult-onset asthma compared | Patients with nonatopic adult-onset asthma and seropositivity to | Brinke et al. 2001 [ |
Severe and obstructive |
| All | Patients with adult-onset asthma | Seropositivity to | Pasternack et al. 2005 [ | ||
| All | 52% with adult-onset asthma |
| Hahn et al. 2012 [ | ||
|
| |||||
|
| All | Healthy controls, severe and nonsevere asthmatics compared | SA-IgE found more often in patients with severe asthma when compared to healthy subjects. Age of asthma onset highest in SA-IgE-positive group. SA-IgE associated with increased risk for asthma, severe asthma, hospitalizations, use of oral steroids, and lower FEV1. | Bachert et al. 2012 [ | Asthma in aged persons? |
| All | Community-based population with adult-onset asthma | Risk factors for presence of SA-IgE were current smoking, older age, male sex, and inhalant allergen sensitization. SA-IgE was associated with current adult-onset asthma. Correlation between SA-IgE and total IgE. | Song et al. 2014 [ | ||
|
| |||||
| TSLP | All | Patients with newly diagnosed asthma (age range 16–98 years) | Smoking attenuated the age-related decrease in total IgE, blood eosinophils, and FeNO and maintained eosinophilic inflammation. Sputum TSLP levels were associated with sputum eosinophil % and pack-years. Current and ex-smokers had higher TSLP versus never-smokers. TSLP may be involved in elevating sputum eosinophils in smokers. | Nagasaki et al. 2013 [ | Smoking asthma |
NR = not reported. ADMA = asymmetric dimethyl arginine, AHR = airway hyperresponsiveness, ECP = eosinophilic cationic protein, EPX = eosinophil peroxidase, MPO = myeloperoxidase, IFN = interferon, IL = interleukin, SA-IgE = Staphylococcus Aureus enterotoxin-specific immunoglobulin E, FEV1 = forced expiratory volume in 1 second, and TSLP = thymic stromal lymphopoietin.